NASDAQ:GNPXGenprex Stock Price, Forecast & News

$3.15

+0.33 (+11.70 %)

(As of 06/4/2020 12:11 PM ET)

Add

Compare

Today's Range

$2.77

Now: $3.15▼

$3.30

50-Day Range

$1.99

MA: $2.70▼

$3.54

52-Week Range

$0.23

Now: $3.15▼

$7.03

Volume5.00 million shs

Average Volume1.29 million shs

Market Capitalization$103.48 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.9

Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Genprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Genprex has a potential upside of 58.7% from its current price of $3.15.
Amount of Analyst Coverage
Genprex has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Genprex has received 193 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Genprex has received 211 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Genprex has received 52.23% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote “Outperform” if you believe GNPX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Genprex does not currently pay a dividend.
Dividend Growth
Genprex does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genprex insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 29.01% of the stock of Genprex is held by insiders.
Percentage Held by Institutions
Only 2.59% of the stock of Genprex is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Genprex are expected to grow in the coming year, from ($0.05) to $0.90 per share.
Price to Book Value per Share Ratio
Genprex has a P/B Ratio of 21.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.31 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GNPX

Previous Symbol

CUSIPN/A

CIK1595248

Webwww.genprex.com

Phone512-370-4081

Debt

Debt-to-Equity RatioN/A

Current Ratio34.48

Quick Ratio33.21

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.15 per share

Price / Book21.00

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-10,650,000.00

Net MarginsN/A

Return on Equity-157.02%

Return on Assets-146.08%

Miscellaneous

EmployeesN/A

Outstanding Shares32,850,000

Market Cap$103.48 million

Next Earnings Date8/11/2020 (Estimated)

OptionableNot Optionable

Receive GNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

Genprex (NASDAQ:GNPX) Frequently Asked Questions

How has Genprex's stock been impacted by COVID-19 (Coronavirus)?

Genprex's stock was trading at $2.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GNPX stock has increased by 30.2% and is now trading at $3.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Genprex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genprex.

When is Genprex's next earnings date?

Genprex is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Genprex.

How were Genprex's earnings last quarter?

Genprex Inc (NASDAQ:GNPX) issued its earnings results on Thursday, May, 14th. The company reported ($0.20) EPS for the quarter. View Genprex's earnings history.

What price target have analysts set for GNPX?

2 brokerages have issued 1-year price objectives for Genprex's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Genprex's share price to reach $5.00 in the next year. This suggests a possible upside of 58.7% from the stock's current price. View analysts' price targets for Genprex.

Has Genprex been receiving favorable news coverage?

News stories about GNPX stock have been trending very negative on Thursday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Genprex earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutGenprex.

Who are some of Genprex's key competitors?

Some companies that are related to Genprex include Humanigen (HGEN), ANI Pharmaceuticals (ANIP), Avid Bioservices (CDMO), Kamada (KMDA), Seres Therapeutics (MCRB), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), Osmotica Pharmaceuticals (OSMT), Kezar Life Sciences (KZR), Selecta Biosciences (SELB), Urovant Sciences (UROV), Geron (GERN), Rigel Pharmaceuticals (RIGL), OrganiGram (OGI) and TherapeuticsMD (TXMD). View all competitors.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), Ibio (IBIO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), FuelCell Energy (FCEL) and vTv Therapeutics (VTVT).

Who are Genprex's key executives?

Genprex's management team includes the following people:

Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Who are Genprex's major shareholders?

Genprex's stock is owned by a number of institutional and retail investors. Top institutional investors include Advisor Group Holdings Inc. (0.20%), IHT Wealth Management LLC (0.13%), Bank of New York Mellon Corp (0.08%), Frontier Wealth Management LLC (0.05%), Mid Atlantic Financial Management Inc. ADV (0.05%) and Jane Street Group LLC (0.03%). Company insiders that own Genprex stock include John Rodney Varner and Julien L Pham. View institutional ownership trends for Genprex.

Which major investors are buying Genprex stock?

GNPX stock was purchased by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., IHT Wealth Management LLC, Bank of New York Mellon Corp, Frontier Wealth Management LLC, Mid Atlantic Financial Management Inc. ADV, and Jane Street Group LLC. Company insiders that have bought Genprex stock in the last two years include John Rodney Varner, and Julien L Pham. View insider buying and selling activity for Genprex.

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $3.15.

How big of a company is Genprex?

Genprex has a market capitalization of $103.48 million.

What is Genprex's official website?

The official website for Genprex is www.genprex.com.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-370-4081 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff